close
MENU
1 mins to read

Stewart, Royston Trust sew up control of Wakefield Health


A joint venture has pre-emptively sewn up control in a partial takeover bid for the private health service provider.

Paul McBeth
Wed, 25 Jul 2012

BUSINESSDESK: A joint venture between Stewart family's interests and the Royston Hospital Trust Board has pre-emptively sewn up control of Wakefield Health in a partial takeover bid for the private health service provider.

The Stewart family and Royston each own 19.99% of Wakefield and have agreement with AMP Capital Investors (New Zealand) to acquire enough of the fund manager’s holding to hold 50.01% via their JV investment vehicle, Austron, according to the notice of takeover.

The $6-a-share offer values the target at $103.6 million, and is a 25% premium to the stock's trading price of $4.80.

AMP Capital will sell between 862,000 and 1.73 million shares, or 5% to 10% of Wakefield, depending on acceptances from other shareholders. That level of acceptances will also scale how much of the Royston and Stewart family stakes are pooled.

All shareholders will be able to sell at least half their shares in the offer.

The notice of takeover has been lodged with the Takeovers Panel today and a formal offer and independent adviser's report will be forthcoming.

In March, the family of Christchurch-based businessman Mark Stewart family exited its 10.2% stake in medical and pet supplies firm Ebos Group.

The Wakefield takeover bid comes ahead of next month's annual shareholders’ meeting, where investors will be asked to change the group's name to Acurity Health Group.

Shareholders will also be asked to lift the pool of directors' fees to $420,000 from $400,000, its first such increase in four years.

In May the hospital operator posted a 27% increase in earnings as demand for ACC-funded surgery made up for flatter private revenue.

Last year the group succeeded in a long-running effort to take over Norfolk Group, which owns 60% of the Grace Hospital in Tauranga, and also bought a 30% stake in Endoscopy Auckland and Labaroscopy Auckland.

The stock is rated "outperform", according to the one analyst recommendation compiled by Reuters, with an enterprise value of $117.7 million.

Paul McBeth
Wed, 25 Jul 2012
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Stewart, Royston Trust sew up control of Wakefield Health
22413
false